96 results on '"Shah, Neil J."'
Search Results
52. A phase 1b study (STELLAR-002) of XL092 administered in combination with nivolumab (NIVO) with or without ipilimumab (IPI) or bempegaldesleukin (BEMPEG) in patients (pts) with advanced solid tumors.
53. A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma.
54. Real-world clinical outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) in current immune-oncology (IO) and tyrosine kinase inhibitors (TKIs) era.
55. Incidence and clinical outcomes of HER2-altered bladder cancer (BC) patients (pts).
56. Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
57. Isolation and characterization of robust plant growth-promoting rhizobacteria from lignite mines, Gujarat
58. Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing
59. PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma
60. PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
61. On the Functional Diversity of Plant Growth-Promoting Rhizobacteria in Bharuch, Gujarat, India
62. PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
63. Immune tolerance with combined allogeneic haplo‐identical haematopoietic stem cell transplant and renal transplant
64. A comprehensive Memorial Sloan Kettering Cancer Center real-world data model: Core clinical data elements.
65. Real-world outcomes of treatment with immune checkpoint inhibitors in unique patient cohorts: Elderly, non-caucasian race, poor performance status, obese, chronic viral infections, and autoimmune diseases.
66. Real-time data quality assurance analysis for real-world, pan-cancer data.
67. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.
68. Late immune-related adverse events with immune checkpoint inhibitors.
69. The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer.
70. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
71. Health Care Resource Use for Modern First-Line Treatments in Metastatic Renal Cell Carcinoma.
72. Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.
73. Automated Identification of Patients with Immune-related Adverse Events from Clinical Notes using Word embedding and Machine Learning
74. Impact of treatment line on outcomes with salvage ipilimumab + nivolumab in metastatic renal cell carcinoma (mRCC).
75. Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis
76. Abstract 3230: Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients with HIV, hepatitis B, or hepatitis C viral infections
77. Real-world outcomes of underrepresented patient populations treated with immune checkpoint inhibitors (ICIs): African American descent, poor ECOG performance status, and chronic viral infections.
78. Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC).
79. Clinical characterization of colitis arising from anti-PD-1 based therapy
80. Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
81. Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs).
82. Product review on the Anti-PD-L1 antibody atezolizumab
83. Clinical presentation of immune-related colitis associated with PD-1 inhibitor monotherapy (MONO) and combination PD-1/CTLA-4 inhibitors (COMBO) in melanoma.
84. Product review on the Anti-PD-L1 antibody atezolizumab.
85. Ustekinumab for the treatment of immune related cutaneous adverse events (ircAEs).
86. Big data in oncology: Challenges and solutions.
87. A single-arm, phase II study of durvalumab (D) and tremelimumab (T) for relapsed/refractory germ cell tumors (GCT).
88. Associations of diet with survival of patients (pts) with metastatic cancer of the urothelium (mUC) and renal cell carcinoma (mRCC) on immune checkpoint blockade (ICB).
89. Germline mutations in hereditary renal cell carcinoma (RCC) genes among 32,240 patients with all cancer types.
90. Genomic determinants of progression-free survival after second line of therapy (PFS-2) for patients on immunotherapy-based combination therapies for advanced clear cell renal cell carcinoma.
91. Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial.
92. Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC).
93. Associations between psychosocial risk factors and immune checkpoint inhibitor outcomes.
94. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis.
95. Clinical characterization of colitis arising from anti-PD-1 based therapy.
96. Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.